AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03563690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment3
Description: 1. Acupoints：treating points are the same to the above group~2. Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes.
Study NCT03563690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment4
Description: 1. Acupoints：Needling points are the same to the above group~2. Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes.
Study NCT03563690 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: treatment5
Description: 1. points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~2. Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 \* 25mm single-use needle with the depth of 1-2mm.
Study NCT03563690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
Study NCT00145470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
Study NCT00145470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo fast dissolving SL tablets, BID
Study NCT00032435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAL-40 Active
Study NCT00032435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAL-40 Placebo
Study NCT00684242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg by mouth daily
Study NCT02629679 — intervention group
Intervention type: BEHAVIORAL
Intervention: Regular scholastic system and organized sports
Description: This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
Study NCT02629679 — intervention group
Intervention type: BEHAVIORAL
Intervention: Regular scholastic system
Description: The group will consist of children who are regularly in school, but not being involved in organized sport activities
Study NCT02378649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
Study NCT02378649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator concomitant with best practice usual care
Study NCT05370287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen inhalation
Description: Subjects will breath 100% oxygen through a mask.
Study NCT05370287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive optics imaging
Description: Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
Study NCT02460393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humanized TNFα monoclonal antibody
Description: Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people
Study NCT01115517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
Study NCT04587921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital oximeter monitoring
Description: Digital oximeter and cardiac frequency monitoring.
Study NCT00412113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: Amlodipine besylate 5 mg
Study NCT00412113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium single pill combination
Description: Amlodipine/atorvastatin single pill combination 10/20 mg
Study NCT00412113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: Amlodipine besylate 10 mg
Study NCT00412113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium single pill combination
Description: Amlodipine/atorvastatin single pill combination 5/20 mg
Study NCT00741806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GHB04L1
Description: single dose intranasal administration of GHB04L1
Study NCT00741806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SPGN buffer
Study NCT02657434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
Study NCT02657434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
Study NCT02657434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
Study NCT02657434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
Study NCT02657434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
Study NCT02460393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous injection of different doses for healthy people
Study NCT00533494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physician feedback (A)
Description: Feedback information to physicians
Study NCT02481466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portfolio diet and structured exercise
Description: Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily.
Study NCT02481466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH-like diet and structured exercise
Description: Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers.
Study NCT02481466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portfolio diet and routine exercise
Description: Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist.
Study NCT03994601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Specified dose on specified days
Study NCT01103726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 1 and 5 mg tablets, 6 mg single dose
Study NCT02481466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH-like diet and routine exercise
Description: Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist.
Study NCT02339519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA CLASSIC
Description: Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
Study NCT02339519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA FASTRACH
Description: Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
Study NCT01103726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: matching placebo tablets, single dose
Study NCT01103726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 1 mg tablets, 3 mg single dose
Study NCT03268902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide Oral Suspension
Description: Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
Study NCT02339519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA SUPREME
Description: Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
Study NCT02657434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
Study NCT02657434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
Study NCT02557334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Strawberry Powder
Description: 40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
Study NCT02557334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Strawberry Powder
Description: 40 g freeze dried strawberry powder
Study NCT02557334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 40 g color and taste matched placebo powder
Study NCT01103726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 5 mg tablets, 15 mg single dose
Study NCT04541732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block
Description: Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
Study NCT04541732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided bilateral quadratus lumborum block
Description: Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
Study NCT04541732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction of general anaesthesia with propofol
Description: propofol: 1.5-2.5mg/Kg
Study NCT04541732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of general anaesthesia with propofol
Description: propofol: 1.5-2.5mg/Kg
Study NCT04541732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxant
Description: Atracurium : 0.5mg/Kg.
Study NCT04541732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscle Relaxant
Description: Atracurium : 0.5mg/Kg.
Study NCT04541732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of general anaesthesia
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen
Study NCT04541732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of general anaesthesia
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen
Study NCT02596828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
Study NCT02596828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
Study NCT02596828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
Study NCT02596828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
Study NCT04399824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-Dose Rate Brachytherapy
Description: Undergo HDR brachytherapy
Study NCT04399824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04399824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04399824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT01103726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablets, single dose
Study NCT02928718 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP
Description: Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
Study NCT03787095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered as an intravenous (IV) infusion
Study NCT03787095 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent for REGN2810, administered as an IV infusion
Study NCT01700647 — intervention group
Intervention type: OTHER
Intervention: Breath test- sampling using ENose
Description: Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
Study NCT01700647 — intervention group
Intervention type: OTHER
Intervention: Laryngoscopy and bronchoscopy
Description: Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
Study NCT04979715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physitherapy follow-up
Description: preoperative patient informaiton, information leaflet and Physiotherapy meeting will be held every 2 weeks for 3 months
Study NCT00810316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alprazolam
Description: Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
Study NCT00810316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alprazolam XR
Description: Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
Study NCT00810316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clonazepam
Description: Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
Study NCT02261350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food fortification
Study NCT02261350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplements
Study NCT01616108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
Study NCT02312908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: For experimental treatment of RBD
Study NCT02312908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill manufactured to mask clonazepam 0.5mg tablet
Study NCT00858143 — intervention group
Intervention type: OTHER
Intervention: Non Interventional Observation
Description: Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
Study NCT02208635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofortified Maize
Description: Participant in this arm were fed zinc biofortified maize (\~30 µg Zn/g).